Vivos Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Vivos Therapeutics Return on Equity (ROE) Growth & History (VVOS)
Vivos Therapeutics's return on equity was −655.01% for fiscal 2025.
View full Vivos Therapeutics company overviewVivos Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −655.01% | −388.76 pp |
| 2024 | 2024-12-31 | −266.25% | +254.97 pp |
| 2023 | 2023-12-31 | −521.22% | −364.04 pp |
| 2022 | 2022-12-31 | −157.19% | −61.61 pp |
| 2021 | 2021-12-31 | −95.57% | +76.99 pp |
| 2020 | 2020-12-31 | −172.56% | — |
Vivos Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −1,323.03% | −1286.83 pp |
| Q3 2025 | 2025-09-30 | −151.79% | −114.45 pp |
| Q2 2025 | 2025-06-30 | −111.52% | −55.82 pp |
| Q1 2025 | 2025-03-31 | −62.52% | +695.39 pp |
| Q4 2024 | 2024-12-31 | −36.20% | +1827.70 pp |
| Q3 2024 | 2024-09-30 | −37.34% | +157.18 pp |
| Q2 2024 | 2024-06-30 | −55.71% | +65.80 pp |
| Q1 2024 | 2024-03-31 | −757.91% | −729.03 pp |
| Q4 2023 | 2023-12-31 | −1,863.89% | −1780.82 pp |
| Q3 2023 | 2023-09-30 | −194.52% | −150.51 pp |
| Q2 2023 | 2023-06-30 | −121.51% | −82.53 pp |
| Q1 2023 · Mar 31 | 2023-03-31 | −28.88% | −5.99 pp |
| Q4 2022 | 2022-12-31 | −83.08% | −57.59 pp |
| Q3 2022 | 2022-09-30 | −44.01% | −28.19 pp |
| Q2 2022 | 2022-06-30 | −38.98% | −25.38 pp |
| Q1 2022 | 2022-03-31 | −22.89% | −5.86 pp |
| Q4 2021 | 2021-12-31 | −25.49% | +63.96 pp |
| Q3 2021 | 2021-09-30 | −15.82% | — |
| Q2 2021 | 2021-06-30 | −13.60% | — |
| Q1 2021 | 2021-03-31 | −17.03% | — |
| Q4 2020 | 2020-12-31 | −89.45% | — |
Vivos Therapeutics return on equity trends
Over the last five fiscal years, Vivos Therapeutics's return on equity decreased from −172.56% to −655.01%, a change of −482.45 percentage points. The latest reported quarter, Q4 2025, shows −1,323.03%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vivos Therapeutics source filings ↗